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Ligands for ErbB1-4 receptor tyrosine kinases, such as epidermal growth factor (EGF)
and neuregulins, regulate brain development and function. Thus, abnormalities in their
signaling are implicated in the etiology or pathology of schizophrenia and Parkinson’s
disease. Among the ErbB receptors, ErbB1, and ErbB4 are expressed in dopamine
and GABA neurons, while ErbB1, 2, and/or 3 are mainly present in oligodendrocytes,
astrocytes, and their precursors. Thus, deficits in ErbB signaling might contribute to the
neurological and psychiatric diseases stemming from these cell types. By incorporating
the latest cancer molecular biology as well as our recent progress, we discuss signal
cross talk between the ErbB1-4 subunits and their neurobiological functions in each cell
type. The potential contribution of virus-derived cytokines (virokines) that mimic EGF and
neuregulin-1 in brain diseases are also discussed.
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INTRODUCTION
ErbB molecules are membrane-spanning receptor tyrosine
kinases that act on epidermal growth factor (EGF) and its deriva-
tives. The ErbB family consists of four members, ErbB1, B2,
B3, and B4, that were originally identified in vertebrates (mam-
mals) and share significant structural homology with mem-
bers of the ErbB family (Downward et al., 1984; Schechter
et al., 1984; Semba et al., 1985; Kraus et al., 1989; Plowman
et al., 1993). ErbB1 homolog is identified also in invertebrates,
C. elegans (LET-23; Aroian et al., 1990) and Drosophila (DER;
Schejter and Shilo, 1989). ErbB receptor family members are
distributed in many organs and cell types originating from
ectodermal and mesodermal tissues and have functions in var-
ious cellular processes/functions such as proliferation, growth,
migration, and adhesion. Upon binding to its ligand such
as EGF and neuregulin-1 (NRG1), the ErbB receptor under-
goes tertiary structural alterations in the juxtamembrane region
and increases its affinity for another an ErbB molecule, lead-
ing to homo- or heterodimerization (Olayioye et al., 2000).
This dimerization allows the kinase domain to phosphorylate
the ErbB partner. The phosphorylated tyrosine residues recruit
adaptor/effecter molecules, such as phosphatidylinositol 3-kinase
(PI3K) subunit p85, Src, and Shc, and transmit signals to
these transducers. As overexpression of ErbB receptors results
in ligand-independent dimerization and auto-phosphorylation,
receptor dimerization, rather than the activation of the kinase
domain, is thought to limit ErbB signaling (i.e., phosphorylation)
(Figure 1).
The primary structure of ErbB1 (EGFR, HER1) was first eluci-
dated among ErbBs. The oncogene v-erbB was identified in avian
erythroblastic leukemia virus. The ortholog and proto-oncogene
of c-erbB was determined to be the gene for EGF receptor, erbB1
(Downward et al., 1984). Following this discovery, homologous
gene cloning led to the identification of the other of ErbB fam-
ily members, including ErbB2 (HER2, Neu), ErbB3 (HER3), and
ErbB4 (HER4) (Schechter et al., 1984; Semba et al., 1985; Kraus
et al., 1989; Plowman et al., 1993). This family shares 40–50%
structural homology in the extracellular domains and 60–80% in
the intracellular domains (Figure 2, Table 1).
THE MOLECULAR FEATURES OF THE ErbB FAMILY
Ligands for ErbB receptors can be classified into two groups:
the EGF family and the NRG family (Falls, 2003; Higashiyama
et al., 2008; Mei and Xiong, 2008). The EGF family consists of
transforming growth factor alpha (TGFα; Derynck et al., 1984),
heparin-binding EGF-like growth factor (HB-EGF; Higashiyama
et al., 1991), amphiregulin (AR; Shoyab et al., 1989), epireg-
ulin (EPR; Toyoda et al., 1995), betacellulin, (BTC; Sasada et al.,
1993; Shing et al., 1993), and epigen (EPG; Strachan et al., 2001).
The NRG family includes NRG1 (Brockes and Kintner, 1986;
Holmes et al., 1992; Peles et al., 1992; Falls et al., 1993; Ho et al.,
1995), NRG2 (NTAK; Higashiyama et al., 1997), NRG3, NRG4
(Hobbs et al., 2002), NRG5 (tomoregulin; Uchida et al., 1999),
and NRG6 (neuroglycan C; Kinugasa et al., 2004). Most of these
ligands are initially synthesized as large membrane-anchored pre-
cursors that are processed into secretable and soluble forms and
then liberated into the extracellular space where they interact
with ErbB receptors (Figure 2). In contrast to this process of
“endocrine signaling,” these precursors are also thought to medi-
ate “juxtacrine signaling” during cell–cell communication; the
membrane-anchored precursors directly bind to ErbB receptors
on the other side of the cell surface (Ono et al., 1994). Please read
the details of “juxtacrine signaling” in other reviews (Iwamoto
and Mekada, 2000; Singh and Harris, 2005).
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FIGURE 1 | ErbB receptor dimerization and activation. The ligand
interaction with ErbB 1, 3, and 4 increases their affinity and induces homo- or
heterodimerization of ErbB1-4. This dimerization activates the tyrosine kinase
domain and allows it to phosphorylate the cytoplasmic region of the ErbB
partner. The phosphorylated tyrosine residues recruit various
adaptors/effectors that induce intracellular signals.
FIGURE 2 | ErbB receptors and their ligands. The molecular structure of ErbB receptors and proteolytic processing of their ligands are displayed.
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Table 1 | ErbB molecules and their ligands and adaptors/effectors.
ErbB receptor Nomenclature Binding partner Ligand Major signaling molecules Other binding proteins
ErbB1 EGF receptor
(EGFR), HER1
ErbB1
ErbB2
ErbB3
ErbB4
EGF EPG
TGFα EPR
HB-EGF
AR
BTC
PI3K-AKT
Ras-MAPK
PLCγ-PKC
Crk FAK JAK
Src PTEN
Cbl
STAT3
ErbB2 Neu, HER2 ErbB1
ErbB3
ErbB4
Unknown PI3K-AKT
Ras-MAPK
FAK Src
Erbin
ErbB3 HER3 ErbB1
ErbB2
ErbB4
NRG1
NRG2
NRG6
PI3K-AKT
Ras-MAPK
PLCγ-PKC
Crk ITK JAK Lyn Src VAV
Cbl
EBP1
TENC1
ErbB4 HER4 ErbB1
ErbB2
ErbB3
ErbB4
HB-EGF NRG2
BTC NRG3
EPG NRG4
NRG1 NRG5
PI3K-AKT
Ras-MAPK
JAK Src Ptprz
N-Cor
PSD95
STAT5
TAB2
Among the ErbB receptors, ErbB3 lacks the active kinase
domain and is unable to phosphorylate ErbB in this dimer com-
plex. However, upon ligand binding, ErbB3 associates with the
heterodimer complex containing the other ErbB and is phospho-
rylated by the partner ErbB kinase, leading to signal transduction
by ErbB3 (Sierke et al., 1997). Conversely, ErbB2 harbors an active
kinase domain, but its high-affinity ligands remain unknown
(Cho et al., 2003; Garrett et al., 2003). The ErbB1 and ErbB2
genes are often amplified and overexpressed in various cancer
cells, resulting in self-dimerization and auto-phosphorylation
in a ligand-independent manner. For instance, ErbB2 is ampli-
fied in 3% of lung cancers, 30% of breast cancers, 20% of
gastric cancers, and 60% of ovarian cancers. The combination
of the ErbB1-4 subunits during heterodimerization does not
appear to be limited; NRG1-bound ErbB4 can associate with
ErbB1 to form a heterodimer, even though ErbB1 is not acti-
vated by EGF (Liu et al., 2012). NRG1 mimics EGF signaling
through ErbB1 phosphorylation in ErbB4:ErbB1 heterodimer
complexes. In the ErbB4:ErbB1 heterodimer, NRG promotes
more threonine phosphorylation and less tyrosine phosphory-
lation of ErbB1, which results in Shc/Grb2 recruitment, than
does EGF (Olayioye et al., 1998). Therefore, even within the
context of the same heterodimer, distinct ligands can differen-
tially impact receptor signaling (Moghal and Sternberg, 1999).
Of note, external stimuli can also affect partnership during ErbB
heterodimerization. Glucocorticoids can interfere with organized
ErbB receptor dimerization in lung cells, leading to a switch from
ErbB1:ErbB4 to ErbB2:ErbB4 heterodimer expression (Table 1;
Dammann et al., 2006). In addition to the signaling complex-
ity and diversity of ErbB heterodimerization, the individual erbB
genes or their products are subjected to alternative splicing or
proteolytic processing, resulting in truncated isoforms lacking the
kinase domain or ligand-binding domain. These truncated iso-
forms function as an enhancer of tumorigenesis, a receptor decoy
or a transcription factor (see below; Yamazaki et al., 1988; Lee
et al., 2001; Vidal et al., 2005; Sundvall et al., 2007; Lin et al., 2008;
Xia et al., 2011; Ward et al., 2012).
CELL SIGNALING AND FUNCTIONS OF INDIVIDUAL ErbB
MOLECULES
All ErbB molecules are expressed not only in peripheral tissues
but also in various neural cells (Table 2). In the view of their func-
tionality in the brain, we need to consider which ErbB subtype is
expressed, where it is expressed, and with which ErbB molecule it
colocalizes or dimerizes. As discussed above, the phosphorylated
ErbB partner determines the functional nature of signaling, irre-
spective of the ErbB ligand. In this context, it is not true that NRG
only evokes the signals of its receptor, ErbB3 and/or ErbB4.
ErbB1 (EGFR, HER1)
ErbB1 signaling links to a large variety of cellular functions,
such as cell survival and proliferation. The down-stream signals
linked to ErbB include the phospholipase Cγ (PLCγ)- protein
kinase C (PKC), Ras- mitogen-activated protein kinase (MAPK),
PI3K-Akt, and janus kinase 2 (JAK2)-STAT3 pathways (Figure 3).
The Ras-MAPK pathway is implicated in cell proliferation and
differentiation, while the PI3K-Akt pathway is involved in cell
growth and anti-apoptotic processes and the PLCγ-PKC pathway
contributes to cell migration and division. The subcellular local-
ization and protein levels of these adaptors/effectors appear to
determine the distinct features of ErbB1 down-stream signals.
ErbB1 has a deletion mutant, EGFRvIII (also known as EGFR,
type3 EGFR, de 2–7 EGFR, EGFR∗), which lacks extracellular
domain of EGFR (Yamazaki et al., 1988). In addition, alter-
native splicing and protein processing produce soluble EGFR
isoform (sEGFR). sEGFR lacks intracellular domain (Flickinger
et al., 1992; Rose-John and Heinrich, 1994; Perez-Torres et al.,
2008). These truncated ErbB1 contribute to tumorigenesis, but
their role in brain is not fully understood (Baron et al., 2003;
Gan et al., 2009).
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Table 2 | Brain distribution and functions of ErbB1-4.
ErbB receptor Tissue Cell type Function
ErbB1 Subventrucular
zone
Neural stem cell Proliferation/
migration
Midbrain Dopaminergic
neuron
Survival/
development
Cortex,
hippocampus
GABAergic
neuron
Astrocyte
Regulation of
synaptic function
Proliferation/
differentiation
Cerebellum Purkinje cell
Granule cell
Astrocyte
Development/
proliferation
Pituitary grand Lactotroph Production/release
of cortisol and
prolactin
ErbB2 Cerebellum,
cortex,
hippocampus,
midbrain, etc.
Oligodendrocyte
Astrocyte
Radial glia
Proliferation/
differentiation
ErbB3 Cortex,
hippocampus,
etc.
Oligodendrocyte Maturation/
myelination
ErbB4 Cortex,
hippocampus,
GABAergic
neuron
Astrocyte
Oligodendrocyte
Attenuates
synaptic function
Proliferation/
differentiation
Cerebellum Granule cell Regulation of
synaptic function
Midbrain Dopaminergic
neuron
Survival, attenuates
synaptic function
In the central nervous system, ErbB1 protein levels are the
highest during the gestational stages and gradually decline dur-
ing development. Consistent with this expression pattern, neural
stem cells in the subventricular zone (SVZ) are highly enriched
with ErbB1 (Abe et al., 2009a). ErbB1 activation triggers the
proliferation and migration of neural stem cells and their imme-
diate decedents (Aguirre et al., 2005, 2010). In addition to these
undifferentiated neural cells, several types of differentiated neu-
rons also maintain expression at postnatal stages. In the mid-
brain region, the nigra-striatal dopamine neurons express ErbB1
together with ErbB4 (Abe et al., 2009a). ErbB1 activation con-
tributes to the survival and postnatal development of dopamin-
ergic neurons, although the molecular nature of the endogenous
ErbB1 ligands has not been fully identified (Iwakura et al., 2005,
2011; Namba et al., 2009). Various types of GABAergic neurons
also carry ErbB1 receptors. Interneurons in the hippocampus
and neocortex as well as cerebella Purkinje cells express ErbB1
(Werner et al., 1988; Seroogy et al., 1995; Namba et al., 2006;
Nagano et al., 2007; Abe et al., 2009b). In contrast to its action
on dopaminergic neurons, the activation of ErbB1 in GABAergic
neurons induces their de-differentiation, as seen in peripheral
cancer cells (Namba et al., 2006; Nagano et al., 2007). The differ-
ences in the biological activities of EGF/ErbB1 signaling between
these two neuronal populations are presumably attributed to dif-
ferences in the ErbB partner. The signal pathways of ErbB1:ErbB1
homodimers and ErbB1:ErbB4 heterodimers differ significantly
as discussed above. In addition to these neurons, astrocytes and
their precursors express ErbB1, which is markedly enhanced
in response to injury-associated astrogliosis (Liu et al., 2006).
ErbB1 is also expressed in the pituitary and regulates the produc-
tion and release of cortisol and prolactin (Cooper et al., 2011;
Dahlhoff et al., 2011). ErbB1 in the hypothalamus reacts with
TGFα, which is produced in the suprachiasmatic nucleus, and
regulates circadian rhythm (Kramer et al., 2001; Snodgrass-Belt
et al., 2005).
ErbB2 (HER2, Neu)
ErbB2 signals mainly link to the Ras-MAPK pathway and the
PI3K-Akt pathway, leading to cell proliferation. Therefore, at
the postnatal stages, ErbB2 levels are limited to postmitotic
neurons or glial cells (Abe et al., 2009a). There are a variety
of truncated ErbB2 isoforms that are produced by alternative
splicing and metalloprotease digestion (Cappuzzo et al., 2012;
Tse et al., 2012; Ward et al., 2012). p110ErbB2 (611CTF) and
p95ErbB2 (CTF648) both lack the extracellular domain and
contribute to cancer progression and metastasis (Xia et al.,
2011; Ward et al., 2012), although their roles in the brain
are poorly understood. The carboxyl terminal of ErbB2 car-
ries a PDZ-binding motif and associates with a leucine-rich
molecule, Erbin (Huang et al., 2001). As Erbin attenuates the
activation of Ras-MAPK signaling linked to cell proliferation, its
interaction with ErbB2 is implicated in oligodendrocyte differ-
entiation and myelination (Tao et al., 2009; Dan et al., 2010;
Liang et al., 2012).
Proliferating neural stem cells or precursors express high
levels of ErbB2 (Abe et al., 2009a) in addition to ErbB1.
Oligodendrocyte precursors express ErbB2 together with ErbB3,
and ErbB2 activation contributes to the proliferation and dif-
ferentiation of these cells via ErbB3 phosphorylation (Flores
et al., 2000). A recent study revealed that signals from
ErbB2:ErbB3 complexes in the neocortex regulate the expres-
sion of disrupted schizophrenia 1 (DISC1), which has been
implicated in the genetics of schizophrenia (Seshadri et al.,
2010). In hippocampal neurons, ErbB2:ErbB4 heterodimers
influence the morphological differentiation of these cells
(Gerecke et al., 2004).
ErbB3 (HER3)
ErbB3 displays ligand preference for some members of the NRG
family; ErbB3 has a high affinity interaction with NRG1, NRG2,
and NRG6. Indeed, the intracellular domain of ErbB3 har-
bors more tyrosine residues that accept various adaptor/effecter
molecules (Table 1). As its kinase activity is impaired, het-
erodimer formation with ErbB2 or the other ErbBs is essential
to evoke signal transduction cascades. Alternative splicing of the
erbB3 gene produces soluble isoforms of ErbB3 (sErbB3) as well
as isoforms with truncations in the intracellular domain (Lee and
Maihle, 1998). Among these isoforms, p45 and p85 sErbB3s bind
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FIGURE 3 | Typical signal transduction from the ErbB4:ErbB1 and
ErbB4:ErbB4 complex. Once ErbB1 is phosphorylated by the partner
ErbB, the following signal cascades are activated; (1) In the PLCγ-PKC
pathway, phosphorylated ErbB1 recruits and associates with PLCγ. As a
result, PLCγ itself is phosphorylated to activate DAG/IP3 signaling (Chen
et al., 1996). (2) In the Ras-MAPK pathway, phosphorylated ErbB1
associates with Shc and interacts with Grb2/Sos1. Activated Sos1
triggers GDP/GTP exchange in Ras and activates Ras, driving the
sequential kinase reactions of Raf(MAPKKK), MEK(MAPKK), and
Erk(MAPK). (3) In the PI3K-Akt pathway, the activated ErbB dimer
interacts with Grb2/Gab1 and forms complexes with activated PI3Kinase,
leading to the conversion of PIP2 to PIP3 and Akt activation. (4) In the
JAK-STAT pathway, ErbB kinase phosphorylates and induces JAK to bind
to ErbB1. Activated JAK phosphorylates STAT and allows STAT to
homodimerize and translocate into the nucleus. Once ErbB4 is
phosphorylated by ErbB4, the signaling cascades linked to differentiation
become activated, notably the PI3K-Akt pathway and the Ras-MAPK
pathway with longer durations.
to NRG and decrease the effective concentrations of NRG1 in the
extracellular space (Lee et al., 2001; Lin et al., 2008). The trun-
cated isoforms of ErbB3 are found in cortical astrocytes andmight
be involved in attenuating NRG signaling (Citri and Yarden, 2006;
Sharif and Prevot, 2010).
In the brain, high ErbB3 expression is only found in oligo-
dendrocytes and their precursors. ErbB3 activation is involved in
their propagation and differentiation (Makinodan et al., 2012).
ErbB3 expression is also observed in neural precursor cells in
the adult hippocampus and contributes to their proliferation,
although ErbB3 expression is modest (Mahar et al., 2011). In
human astrocytes, ErbB3, and ErbB1 form heterodimers that
transduce NRG-dependent signals (Sharif et al., 2009). Again,
EGF evokes NRG-like signaling through the dimerization of
ErbB3 and ErbB1.
ErbB4 (HER4)
ErbB4 mainly links to the Ras-MAPK and PI3K-Akt pathways.
In contrast to ErbB1 signaling, ErbB4 phosphorylation induces
sustained activation of the Ras-MAPK pathway, leading to cell
cycle cessation and differentiation (Muraoka-Cook et al., 2008;
Ortega et al., 2012). In the erbB4 genome, alternative splicing of
exon 15/16 and exon 26 produces ErbB4 variants, JM-a/b/c/d and
CYT-1/2, respectively (Figure 4; Zeng et al., 2009; Veikkolainen
et al., 2011). The phosphorylation of CYT-1 can recruit the
p85 adaptor to activate PI3K-Akt signaling (Kainulainen et al.,
2000). The CYT-1 sequence is susceptible to proteolytic cleav-
age by TNF-alpha converting enzyme (TACE) and γ-secretase
(Vidal et al., 2005; Sundvall et al., 2010). Thus, ErbB4 proteol-
ysis produces an 80 kD intracellular fragment (ErbB4-ICD) and
liberates it into the cytoplasmic space. ErbB4-ICD interacts with
the transcription factor STAT5 and migrates into the nucleus as a
molecular chaperone (Vidal et al., 2005; Sundvall et al., 2010).
ErbB4 also contains a PDZ-binding motif at the carboxyl ter-
minal and is anchored to postsynaptic density protein 95 (PSD95)
in neurons (Huang et al., 2000). Even when proteolytic cleav-
age produces ErbB4-ICD or when ErbB4 is phosphorylated with
the ErbB partner, the signal is only minimally transported to
the soma or translocated into the nucleus. Rather, the interac-
tion with the scaffold protein PSD95 allows NMDA receptors to
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FIGURE 4 | Splice variants of ErbB4 proteins and their specific
signaling. The JM-a and JM-d isoforms of ErbB4 are cleaved by TACE or
γ-secretase and converted to ErbB4-ICD. ErbB4-ICD is translocated into
the nucleus with STAT and regulates gene transcription (A). The CYT-1 and
CYT-2 isoforms of ErbB4 differentially trigger Ras-MAPK signaling and/or
PI3K-Akt signaling (B).
interact with ErbB4 and restrict ErbB4 signaling to the postsy-
naptic compartments (Garcia et al., 2000). Accordingly, impaired
NRG1/ErbB4 signal is thought to underlie NMDA receptor dys-
function found in brain diseases such as schizophrenia (Hahn
et al., 2006; Pitcher et al., 2011). ErbB4 also can form molecular
complexes with the receptor-type tyrosine phosphatase (Ptprz)
via its interaction with PSD95 (Fujikawa et al., 2007). In this
complex, Ptprz interacts with ErbB4 as its substrate and de-
phosphorylates ErbB4. Given the ligands for Ptprz (i.e., mid-
kines and pleiotropins), NRG/ErbB4 signals can be disrupted by
other cytokines through this receptor-type tyrosine phosphatase
(Figure 5).
ErbB4 expression gradually increases in the brain and becomes
pronounced in postmitotic neurons such as GABAergic interneu-
rons, dopamine neurons, and cerebellar granule cells (Table 2;
Elenius et al., 1997; Abe et al., 2009a; Vullhorst et al., 2009).
The developmental pattern of ErbB4 expression is the opposite
of that of ErbB1 (Abe et al., 2009a). ErbB4 signals may accelerate
neural differentiation in these cell populations, potentially atten-
uating ErbB1 signaling (Woo et al., 2007; Fazzari et al., 2010).
The NRG-driven up-regulation of glutamate receptor functions
may represent the typical phenotypic responses of this cell popu-
lation; ErbB4 activation regulates the activity and/or expression
of both AMPA-type and NMDA-type glutamate receptors in
GABAergic neurons (Gajendran et al., 2009; Abe et al., 2011;
Ting et al., 2011). ErbB4 in midbrain dopaminergic neurons
regulates the enzyme activity and expression of tyrosine hydrox-
ylase in vivo as well as dopamine synthesis and release (Kato
et al., 2011). Although ErbB4 is suggested to contribute to the
migration and differentiation of immature GABAergic interneu-
rons, these processes also involve ErbB1, and thus, the interplay
between ErbB4 and ErbB1 needs to be characterized to reveal
the full mechanism (Mahar et al., 2011; Li et al., 2012). In
our previous studies, these phenotypic actions of NRG1/ErbB4
signals appear to be more modest than those of EGF/ErbB1
signals in neural cultures. Consistent with these findings, the
gross brain structures and function of ErbB4-null knockout
mice appear to be modest compared with ErbB1-null knock-
out mice (Sibilia and Wagner, 1995; Sibilia et al., 1998; Thuret
et al., 2004). In this context, the crucial functions and/or bio-
logical significance of ErbB4 in the brain might not be fully
characterized.
IMPLICATIONS OF ABNORMAL ErbB SIGNALING IN BRAIN
DISEASES
ErbB signaling contributes to the development and maintenance
of various cell populations in the central nervous system and is
therefore implicated in the etiology or neuropathology of vari-
ous brain diseases such as schizophrenia and Parkinson’s disease,
which involve cell dysfunction of GABAergic and/or dopaminer-
gic neurons. Here we would like to discuss the potential patholog-
ical links between ErbB signaling and these brain diseases.
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FIGURE 5 | Synaptic compartment of ErbB4 that binds to PSD95
or interacts with the phosphatase. The scaffolding protein PSD95
anchors ErbB4 and the NMDA receptor at postsynaptic sites. The
molecular interaction between ErbB4 influences NMDA receptor
activity and function (A). The PSD95-mediated interaction between
ErbB4 and a membrane attached phosphatase, Ptprz. Ptprz
eliminates the phosphate from ErbB4 and attenuates its
signaling (B).
PARKINSON’S DISEASE
Parkinson’s disease is a progressive neurodegenerative disorder
in which patients exhibit obvious symptoms of motor dysfunc-
tion, such as shaking and muscle rigidity. This disease progresses
to neurodegeneration of the midbrain dopaminergic neurons.
Consistent with the neurotrophic actions of EGF on this cell pop-
ulation, the protein levels of EGF and ErbB1 are diminished in
the postmortem brains of patients with this disease (Iwakura
et al., 2005). A neurotrophic disturbance in ErbB1 signaling is
reproduced in animal models of the disease; rats receiving a
dopaminergic neurotoxin exhibit decreased ErbB1 and dopamin-
ergic cell loss but EGF ameliorates these deficits (Pezzoli et al.,
1991; Ventrella, 1993; Iwakura et al., 2005). Similarly, the con-
tribution of ErbB4 signals to this illness is under investigation.
Because of the higher blood-brain permiability of type 1 NRG1
(Kato et al., 2011), NRG1 was peripherally administeration to
a Parkison’s disease model to induce the neuroprotection of
dopamine neurons (Zhang et al., 2004; Carlsson et al., 2011;
Depboylu et al., 2012).
The molecular neuropathology of Parkinson’s disease involves
not only ErbB1 but also ErbB-interacting molecules. For exam-
ple, LINGO-1, which associates with the Nogo-receptors in the
nervous system, directly binds to ErbB1 to attenuate cell sur-
vival signals (i.e., PI3K-Akt signaling) in dopamine neurons
(Inoue et al., 2007). Consistent with this finding, LINGO-1
expression is elevated in the substantia nigra of patients
with Parkinson’s disease. The molecule parkin, which is the
causative gene for inheritable Parkinson’s disease (Kitada et al.,
1998), maintains ErbB1 signaling under normal conditions.
Parkin can promote the ubiquitination and dissociation of
Eps15 from ErbB1 to attenuate the internalization and degra-
dation of ErbB1 (Fallon et al., 2006). Conversely, mutations
in the parkin gene result in accelerated ErbB1 degradation,
leading to the loss of neurotrophic ErbB1 signals in this
disease.
SCHIZOPHRENIA
ErbB1 as well as ErbB4 is distributed in all the cell populations
that are implicated in schizophrenia neuropathology, includ-
ing GABAergic neurons, dopaminergic neurons, and glial cells.
Several studies have focused on the ErbB1 molecule. Postmortem
studies revealed that the ErbB1 protein is up-regulated in the fore-
brain regions of schizophrenia patients (Futamura et al., 2002).
Animal studies demonstrate that acute and subchronic brain acti-
vation of ErbB1 triggers dopamine release in the striatum or
globus pallidus, leading to behavioral impairments relevant to
schizophrenia (Futamura et al., 2003; Tohmi et al., 2005; Mizuno
et al., 2008; Sotoyama et al., 2011). In contrast to the effects on
dopamine neurons, ErbB1 ligands negatively regulate GABAergic
development in the neocortex and attenuate the activity of glu-
tamate receptor channels in these neurons (Namba et al., 2006;
Nagano et al., 2007). Conversely, quianozoline ErbB1 inhibitors
can ameliorate schizophrenia-related behaviors in various ani-
mal models for schizophrenia (Mizuno et al., 2008). Both types
of model studies indicate a pathological link between ErbB1
hypersignaling and schizophrenia. Given that ErbB1 and ErbB4
colocalization within the same neurons, it is likely that ErbB1
competes with NRG/ErbB4 signals, as was suggested in cancer
studies (Moghal and Sternberg, 1999; Pitfield et al., 2006; Das
et al., 2010).
Genetic studies have also demonstrated that schizophrenia is
associated not only with the ligand NRG but also with its receptor
ErbB4 (Stefansson et al., 2002). In 2006, SNP analysis revealed
a genetic association between the erbB4 gene and a particular
type of splicing pattern associated with this illness (Norton et al.,
2006; Silberberg et al., 2006). The risk of erbB4 SNPs appears
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to correlate with the disease-specific spicing pattern (i.e., JM-a
and CYT-1) in the prefrontal cortex and hippocampus of patients
(Law et al., 2007; Tan et al., 2010). A postmortem study also found
an increase in phosphorylated ErbB4 protein and its ability to
form complexes with PSD95 but failed to detect a difference in
total ErbB4 levels in schizophrenia patients (Hahn et al., 2006).
In addition to the neuropathology of GABAergic and
dopaminergic neurons in schizophrenia, postmortem studies
indicate the deficits in white matter and myelin structures are
associated with this illness (Davis et al., 2003; Flynn et al., 2003).
ErbB3 signals play crucial roles in oligodendrocyte myelination
and saltatory conduction of nerve impulses (Stewart and Davis,
2004). Thus, several schizophrenia studies have focused on ErbB3
function. Aston et al. (2004) found that mRNA levels of genes
related to myelin and oligodendrocytes, including erbB3 mRNA,
are down-regulated in the middle temporal gyrus of schizophre-
nia patients (Aston et al., 2004). However, the genetic association
between erbB3 SNPs and schizophrenia remains controversial
(Kanazawa et al., 2007; Watanabe et al., 2007). In addition to
the genetic association between erbB SNPs and schizophrenia,
viral infection also directly triggers ErbB signaling and potentially
contributes to brain mal-development.
IMPACT OF VIROKINES ON ErbB SIGNALING
Virokine is a general term for a cytokine produced by viruses. By
producing virokines, many viruses perturb the immune defense
system of host organisms to escape clearance or promote host cell
proliferation to enhance viral propagation (Klouche et al., 2004).
A variety of virokines have been identified, including those that
act on ErbB receptors (Table 3). In fact, some virokines are sug-
gested to impair brain development (Billings et al., 2004). Thus,
virokine production following viral infection directly influences
brain development and might support the schizophrenia hypoth-
esis of viral infection (Waddington and Buckley, 1996; Brown and
Derkits, 2010).
Vaccinia virus growth factor (VGF, Vaccinia virus 19-
kilodalton protein) is encoded by the genome of vaccinia virus
in the poxvirus family and has an amino acid sequence homol-
ogous to EGF (Figure 6). VGF is produced and secreted from
its membrane-anchored precursor and binds to ErbB1 receptors.
VGF activates the Ras-MAPK pathway of host cells and pro-
motes cell proliferation (Eppstein et al., 1985; Twardzik et al.,
1985). Cowpox virus growth factor (CGF) displays high homol-
ogy to VGF and enhances host cell propagation (da Fonseca et al.,
1999). Additional EGF-like virokines have been identified in other
pox viruses, including smallpox virus growth factor (SPGF; Kim
et al., 2004), myxoma virus growth factor (MGF; Opgenorth
et al., 1993), and shope fibroma virus growth factor (SFGF; Chang
et al., 1987; Ye et al., 1988). These virokines also carry an EGF-
like sequence and interact with ErbB receptors. According to the
schizophrenia hypothesis of maternal and perinatal viral infec-
tion, the infection of these viruses and their translocation to
the brain may perturb the normal development of dopamin-
ergic or GABAergic neurons, although this assumption is fully
hypothetical.
In addition to soluble virokines, virus-derived effectors can
affect intracellular ErbB signaling. E5 is one of the early gene
products of human papillomaviruses. E5 protein is also a
Table 3 | Virokines that bind to ErbB receptors.
Virokine (ErbB-binding proteins) Receptors Related
proteins
VGF VGF
(Vaccinia virus growth
factor, vaccinia 19kd
protein)
ErbB1
homodimer
EGF, TGFα
CGF
(Cowpox growth factor)
ErbB1 VGF
EGF family
SPGF
(Smallpox growth
factor)
ErbB1 VGF
EGF family
SFGF
(Shope fibroma virus
growth factor)
ErbB1 containing
dimer
VGF
EGF family
MGF
(Myxoma virus growth
factor)
ErbB2/ErbB3 VGF
EGF family
E5 protein Human papilloma virus
type16 E5 protein
ErbB1
ErbB4 (JM-b
CYT-1)
Human papillomavirus
type6 E5 protein
ErbB1, ErbB2
Bovine papillomavirus
type1 E5 protein
ErbB1
membrane-anchored molecule, like the EGF precursor, but lacks
the EGF-like domain. For example, the E5 protein of human
papillomavirus type 16(HPV-16) associates with the ATPase
motif of the ErbB1 tyrosine kinase domain, attenuate its inter-
action with Cbl, and inhibits the internalization and degrada-
tion of ErbB1 (Figure 6). Accordingly, papillomavirus infection
enhances EGF/ErbB1 signaling to promote host cell prolifera-
tion (Chang et al., 2001; Venuti et al., 2011; Ganguly, 2012).
In addition to ErbB1, the E5 protein also binds to the JM-
b/CYT-1 isoform of ErbB4 and promotes host cell survival
(Chen et al., 2007). The E5 protein in other papillomaviruses
(human papillomavirus type 6 and bovine papillomavirus type1)
exerts similar modifications on ErbB signaling (Martin et al.,
1989; Cohen et al., 1993; Conrad et al., 1994). It is noteworthy
that the human uterus can be infected with human papillo-
mavirus type 16. Assuming that a human embryo develops in a
uterus harboring papillomavirus, the potential direct or indirect
impact of the E5 protein on fetal brain development cannot be
overlooked.
PROVISIONAL CONCLUSION
Studies in cancer biology clearly indicate the pathologic powers
of abnormal ErbB signaling and its contribution to oncogenesis,
asthma, injury repair, and rheumatoid arthritis (Stoll and Elder,
1998; Davies et al., 1999; Satoh et al., 2001; Bersell et al., 2009;
Calvo et al., 2010; Finigan et al., 2011; Yarden and Pines, 2012).
In contrast to our knowledge of ErbB signaling in the periphery,
the biological functions and regulation of ErbB signaling in the
brain are still limited (Buonanno and Fischbach, 2001; Wong and
Guillaud, 2004; Mei and Xiong, 2008). The ligand-bound ErbB
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FIGURE 6 | Primary sequences of ErbB-interacting virokines and
receptor interactions. The primary amino acid sequences of EGF
and virokines in the poxvirus family are shown (A). An ErbB
adaptor, E5, which is produced by papillomaviruses, associates
with the kinase domain of ErbB and inhibits its internalization
and/or degradation (B).
receptor does not transmit signals, and instead the ErbB partner
acts as a kinase substrate to trigger intracellular signaling. In addi-
tion, we need to consider which individual ErbB splicing isoforms
are expressed in individual neural cells because some ErbB iso-
forms have a dominant-active or -negative function. Currently,
we only know that erbB gene products are present in certain
neurons or glia and not the real structures of particular ErbB iso-
forms in various brain regions. In this context, a more elaborate
analysis may be required to accurately discuss their functions in
the nervous system.
Although there are a total of four ErbB molecules, their lig-
ands have significantly more diversity. There are six endogenous
ErbB ligands in the EGF family and six in the NRG family. Virus-
derived ErbB ligands also need to be considered. In contrast to
the investigations on EGF or NRG1, the contribution of the other
ligands, such as HB-EGF and NRG6 (neuroglycan C), is poorly
understood even though those are highly expressed in the brain
(Kinugasa et al., 2004; Nakanishi et al., 2006; Oyagi et al., 2009,
2011). Together with the proteolytic regulation of ErbB proteins
and ligand precursors, ErbB signaling is regulated at multiple lev-
els, including SNPs, alternative splicing, proteolytic processing,
intracellular translocation, and signal cross talks between ErbBs.
We hope this review will hint at the biological importance of ErbB
in the nervous system and drive readers to challenge biological or
pathological questions regarding ErbB signaling.
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